Malic Acid Plus Immunotherapy for Solid Tumors
Part of Cancer clinical trials.
This study tests whether adding malic acid (a natural compound) to your ongoing immunotherapy can help fight solid tumors like colorectal, lung, or melanoma. It is an early-stage trial for people who are already getting immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a solid tumor cancer like colorectal, lung, or melanoma.
- You have at least one tumor that can be measured on a scan.
- You are currently receiving immunotherapy.
- Your blood counts and other lab tests are mostly normal.
- You do not have serious heart, lung, or brain problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational treatment called LM303 for people with advanced solid tumors like melanoma, lung cancer, or cervical cancer. It uses your own immune cells (called TILs) to fight the cancer, so you need a tumor large enough for cells to be collected.
This trial tests whether a special diet low in certain amino acids (building blocks of protein), combined with an immune-boosting antibody drug, can safely shrink stage III melanoma that has spread to lymph nodes. The goal is to see if this combination works better than standard treatment.
This trial tests a new immune cell therapy for people with advanced solid tumors of the lung, liver, colon, rectum, or breast. It aims to see if the treatment is safe and can help shrink or control the cancer.
This Phase 1 study tests LM103 to treat advanced cancers that are not responding to standard treatment. It also looks at whether enough tumor tissue can be collected for immune cell testing, and focuses on safety at first.
This early-phase trial tests a new type of cancer vaccine designed to help your immune system attack tumors. It is for people with advanced solid tumors who have run out of standard options.
This trial tests whether intravenous vitamin C (ascorbic acid) combined with an immune treatment (adebrelimab) can slow or shrink metastatic colorectal cancer that can’t be removed with surgery. It focuses on tumors that strongly show a specific marker called GLUT3, and aims to see if the combination works better than standard approaches.
Hear when a new Solid Tumor Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.